DIVA Laboratories Ltd (4153) - Total Assets
Based on the latest financial reports, DIVA Laboratories Ltd (4153) holds total assets worth NT$1.38 Billion TWD (≈ $43.59 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DIVA Laboratories Ltd - Total Assets Trend (2017–2025)
This chart illustrates how DIVA Laboratories Ltd's total assets have evolved over time, based on quarterly financial data. Also see DIVA Laboratories Ltd (4153) market capitalisation for the company's overall valuation and market capitalisation.
DIVA Laboratories Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
DIVA Laboratories Ltd's total assets of NT$1.38 Billion consist of 80.1% current assets and 19.9% non-current assets. Review 4153 total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 36.5% |
| Accounts Receivable | NT$285.50 Million | 21.1% |
| Inventory | NT$249.82 Million | 18.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$996.00K | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how DIVA Laboratories Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest DIVA Laboratories Ltd stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DIVA Laboratories Ltd's current assets represent 80.1% of total assets in 2025, an increase from 68.2% in 2017.
- Cash Position: Cash and equivalents constituted 36.5% of total assets in 2025, up from 26.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 21.1% of total assets.
DIVA Laboratories Ltd Competitors by Total Assets
Key competitors of DIVA Laboratories Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €439.78K |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
DIVA Laboratories Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.50 | 2.90 | 5.53 |
| Quick Ratio | 1.82 | 2.43 | 3.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$670.84 Million | NT$695.52 Million | NT$671.09 Million |
DIVA Laboratories Ltd - Advanced Valuation Insights
This section examines the relationship between DIVA Laboratories Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | NT$1.35 Billion |
| Market Capitalization | $58.41 Million USD |
Valuation Analysis
Below Book Valuation: The market values DIVA Laboratories Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: DIVA Laboratories Ltd's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for DIVA Laboratories Ltd (2017–2025)
The table below shows the annual total assets of DIVA Laboratories Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.35 Billion ≈ $42.65 Million |
+3.69% |
| 2024-12-31 | NT$1.31 Billion ≈ $41.13 Million |
+4.96% |
| 2023-12-31 | NT$1.24 Billion ≈ $39.18 Million |
-0.64% |
| 2022-12-31 | NT$1.25 Billion ≈ $39.44 Million |
+5.93% |
| 2021-12-31 | NT$1.18 Billion ≈ $37.23 Million |
+6.15% |
| 2020-12-31 | NT$1.11 Billion ≈ $35.07 Million |
-14.46% |
| 2019-12-31 | NT$1.30 Billion ≈ $41.00 Million |
-1.62% |
| 2018-12-31 | NT$1.32 Billion ≈ $41.68 Million |
+24.61% |
| 2017-12-31 | NT$1.06 Billion ≈ $33.45 Million |
-- |
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is he… Read more